A Single-center, Non-randomized Controlled, Single-arm, Phase II Clinical Trial of Sintilimab in Combination With Axitinib in the Treatment of Advanced Renal Cell Carcinoma
Overview
- Phase
- Phase 2
- Intervention
- Sintilimab
- Conditions
- Renal Cell Carcinoma
- Sponsor
- Tianjin Medical University Second Hospital
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Overall response rate (ORR)
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
In patients with recurrent or metastatic renal cell carcinoma, a preliminary evaluation of the safety and efficacy of sintilimab combined with axitinib in patients with advanced renal cell carcinoma was conducted.Progression-free survival (PFS), overall survival (OS), disease control rate (DCR) and disease remission rate (ORR) were evaluated.
Detailed Description
Patients with recurrent or metastatic renal cell carcinoma received axitinib tablets (5mg bid po) combined with sintilimab (200mg d1) on a 3-week (21-day) as a one-cycle regimen.6 months of continuous administration (i.e., 8 cycles of sintilimab) or until tumor progression or unacceptable toxicity or death or subject withdraws informed consent;If the drug has been discontinued or the tumor has progressed, and there are no intolerable side effects, the drug can be continued according to the judgment of the researchers and the will of the subjects. Drug safety was evaluated before each cycle.The first efficacy was evaluated after 2 cycles.The efficacy was then evaluated every 2 cycles.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed written informed consent before performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up
- •Diagnosis of locally advanced or metastatic RCC that is predominantly clear cell histology
- •Must have measurable disease
- •Subject has received no prior systemic therapy
- •A woman is eligible to participate in the study if she is of Non-childbearing potential, has a negative serum pregnancy test within 7 days of the first dose of study treatment, not lactating, and agrees to use adequate contraception during the study until at least 120 days after the last dose of investigational product
- •Eastern Cooperative Oncology Group performance status 0 or 1
- •Adequate organ function as defined in the protocol
- •Left ventricular ejection fraction \>= lower limit of normal as assessed by echocardiogram or multigated acquisition scan
Exclusion Criteria
- •Subject has an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents
- •Subject is currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of the first dose of study treatment
- •Subject is expected to require any other form of systemic or localized antineoplastic therapy while on study
- •Subject is on any systemic steroid therapy, within one week before the planned date for first dose of study treatment. Subject is on any other form of immunosuppressive medication
- •Unable to swallow and retain orally administered medication
- •Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other -Gastrointestinal conditions with increased risk of perforation; history of abdominal fistula, GI perforation, or intra-abdominal abscess within 4 weeks before beginning study treatment
- •Known history of HIV infection or a known history of or is positive for Hepatitis B or Hepatitis C
- •Presence of active infection requiring systemic therapy
- •Corrected QT interval duration prolongation
- •History of any one or more of the following cardiac conditions within the past 6 months: Cardiac angioplasty or stenting; Myocardial infarction; Unstable angina; ----History of Class III or IV congestive heart failure according to New York Heart Association classification
Arms & Interventions
Patients with advanced RCC
Patients with a diagnosis of kidney cancer (renal cell carcinoma, advanced or metastatic, previously treated or untreated)
Intervention: Sintilimab
Patients with advanced RCC
Patients with a diagnosis of kidney cancer (renal cell carcinoma, advanced or metastatic, previously treated or untreated)
Intervention: Axitinib
Outcomes
Primary Outcomes
Overall response rate (ORR)
Time Frame: Up to 12 months
To be assessed by RECIST 1.1
Secondary Outcomes
- Progression free survival (PFS)(From randomization up to 3 years.)
- Overall Survival (OS)(Every 3 months up to 3 years.)
- Disease Control Rate (DCR)(Every 6 weeks up to 18 months from patient enrollment in the study, then every 12 weeks up to 3 years from randomization)
- Incidence of treatment-related adverse events(Up to 3 years.)